Health Technology Assessment zur medizinischen Wirksamkeit und Kosten-Effektivität der Phototherapeutischen Keratektomiemit dem Excimerlaser bei rezidivierenden Erosionen, Hornhautdystrophien, Hornhautdegenerationen und oberflächlichen Hornhautnarben

Hintergrund und Fragestellung: Die phototherapeutische Keratektomie mit dem Excimer-Laser (PTK) wird bei rezidivierenden Hornhauterosionen, oberflächlichen Hornhautdystrophien, zentralen Hornhautdegenerationen, oberflächlichen Hornhautnarben und -irregularitäten mittlerweile weit verbreitet als Therapie eingesetzt. Beim Großteil der Indikationen gibt es nach Ausschöpfung konservativer Maßnahmen, abgesehen von der Hornhautstichelung bei rezidivierenden Erosionen und der Keratoplastik bei Hornhautdystrophien und Hornhautnarben, keine therapeutischen Alternativen. Bisher wurde die PTK bei diesen Indikationen noch nicht in den Leistungskatalog der GKV aufgenommen. Der vorliegende HTA-Bericht sollte die wissenschaftliche Evidenz zusammentragen, inwiefern der medizinischen Nutzen, die medizinischen Notwendigkeit und die Wirtschaftlichkeit der PTK bei den genannten Indikationen nachgewiesen werden können. --

WW Scattering Parameters via Pseudoscalar Phase Shifts

Using domain-wall lattice simulations, we study pseudoscalar-pseudoscalar scattering in the maximal isospin channel for an SU(3) gauge theory with two and six fermion flavors in the fundamental representation. This calculation of the S-wave scattering length is related to the next-to-leading order corrections to WW scattering through the low-energy coefficients of the chiral Lagrangian. While two and six flavor scattering lengths are similar for a fixed ratio of the pseudoscalar mass to its decay constant, six-flavor scattering shows a somewhat less repulsive next-to-leading order interaction than its two-flavor counterpart. Estimates are made for the WW scattering parameters and the plausibility of detection is discussed.Comment: 8 pages, 6 figure

Going global: The introduction of the Asian isopod Ianiropsis serricaudis Gurjanova (Crustacea: Peracarida) to North America and Europe

The Asian isopod Ianiropsis serricaudis is now well established in fouling communities, often associated with introduced ascidians, throughout the Northern Hemisphere but has gone largely unnoticed because of its diminutive size (typically less than 3 mm in length) and the difficulties of identifying small peracarid crustaceans. Known locations include the northeastern Pacific (Puget Sound, San Francisco Bay, and Monterey Bay), the northwestern Atlantic (from the Gulf of Maine to Barnegat Bay, NJ), and the northeastern Atlantic (England and the Netherlands). We predict that this species is widespread along North America and European coasts, and may already be introduced to cold temperate waters of the Southern Hemisphere as well

Capturing the value of vaccination within health technology assessment and health economics:Country analysis and priority value concepts

Background: A value of vaccination framework for economic evaluation (EE) identified unique value concepts for the broad benefits vaccination provides to individuals, society, healthcare systems and national economies. The objectives of this paper were to work with experts in developed countries to objectively identify three priority concepts to extend current EE. Methods: The previously developed classification of value concepts in vaccination distinguished 18 concepts, categorised as conventional payer and societal perspective concepts and novel broader societal concepts. Their inclusion in current EE guidelines was assessed. Experts identified eight criteria relevant to decision-making and measurement feasibility, which were weighted and used to score each concept. The relative ranking of concepts by importance and the gaps in guidelines were used to identify three priority concepts on which to focus immediate efforts to extend EE. Results: The EE guidelines review highlighted differences across countries and between guidelines and practice. Conventional payer perspective concepts (e.g., individual and societal health gains and medical costs) were generally included, while gaps were evident for conventional societal perspective concepts (e.g., family/caregiver health and economic gains). Few novel broader societal benefits were considered, and only in ad hoc cases. The top-three concepts for near-term consideration: macroeconomic gains (e.g., benefiting the economy, tourism), social equity and ethics (e.g., equal distribution of health outcomes, reduced health/financial equity gaps) and health systems strengthening, resilience and security (e.g., efficiency gains, reduced disruption, increased capacity). Conclusions: Gaps, inconsistencies and limited assessment of vaccination value in EE can lead to differences in policy and vaccination access. The three priority concepts identified provide a feasible approach for capturing VoV more broadly in the near-term. Robust methods for measuring and valuing these concepts in future assessments will help strengthen the evidence used to inform decisions, improving access to vaccines that are demonstrably good value for money from society's point of view. (C) 2022 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd

Capturing the value of vaccination within health technology assessment and health economics:Literature review and novel conceptual framework

Background: Vaccination provides significant health gains to individuals and society and can potentially improve health equity, healthcare systems and national economies. Policy decisions, however, are rarely informed by comprehensive economic evaluations (EE) including vaccination's wide-ranging value. The objective of this analysis was to focus on health technology assessment systems to identify relevant value concepts in order to improve current EE of non-pandemic vaccines. Methods: Following a literature review, a novel Value of Vaccination (VoV) framework was developed with experts in vaccine EE from developed countries with established health technology assessment systems. Results: Forty-four studies presenting value frameworks or concepts applicable to vaccination were included. Eighteen unique value concepts relevant to EE were identified and defined. These were categorised within the VoV framework using three dimensions, moving from a narrow payer perspective to a more expansive and societal perspective. The dimensions were: (I) conventional payer perspective concepts (e.g., health gains in vaccinees, direct medical costs); (II) conventional societal perspective concepts (e.g., indirect health/economic gains to caregivers/households, productivity in vaccinees); and (III) novel societal concepts (e.g., financial risk protection, peace of mind, societal health gains, healthcare systems security, political stability, social equity and macroeconomic gains). While good quality evidence and methods are available to support concepts in Dimensions I and II, further work is needed to generate the required evidence for vaccination impact on Dimension III concepts. Conclusions: The devastating effect on nations of the COVID-19 pandemic has helped to highlight the potential far-reaching benefits that many vaccination programmes can offer. This VoV framework is particularly relevant to policy decisions considering EE, and the potential future expansion of non-pandemic vaccination value considerations. The framework helps to understand and compare current value considerations across countries and payer versus societal perspectives. It provides decision-makers with a transparent and logical path to broaden consideration of VoV in EE. (C) 2022 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd

Front Surface Spectral Control Development for TPV Energy Conversion (a Presentation)

This paper discusses the introduction to the potential of alternative materials that provide higher temperature stability than current materials. The outline of this report is: (1) Review briefly the importance of spectral control; (2) Provide current results; (3) Introduce the temperature stability issue; (4) Describe the requirements for alternate materials and (5) Present alternative materials. The conclusions of this report are: (1) Antimony selenide has achieved the highest spectral efficiency to date; (2) Several materials expected to have higher temperature stability have been shown to be viable; (3) So far, with limited development, the performance of the these materials is lower than Antimony selenide; and (4) Additional development will be required to achieve similar or higher performance

Optical Coatings for Thermophotovoltaic Spectral Control

The efficiency of thermophotovoltaic (TPV) energy conversion is dependent on efficient spectral control. An edge pass filter (short pass) in series with a highly doped, epitaxially grown layer has achieved the highest performance of TPV spectral control. Front surface, tandem filters have achieved the highest spectral efficiency and represent the best prospect for even higher spectral efficiency for TPV energy conversion systems. Specifically, improvements in the physical vapor deposition process, identification of other materials with a high index of refraction and a low absorption coefficient, and more efficient edge filter designs could provide higher TPV spectral performance